Meeting
2021 ASCO Annual Meeting
Doubling of median overall survival in a nationwide cohort of veterans with stage III non-small cell lung cancer in the durvalumab era.
Authors
Kamya Sankar
Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
Kamya Sankar , Alex K. Bryant , Michael Green , Nithya Ramnath
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8546)
DOI
10.1200/JCO.2021.39.15_suppl.8546
Abstract #
8546
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.
First Author: Jarushka Naidoo
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto
Poster
2023 ASCO Quality Care Symposium
Management and treatment of patients (pts) with stage III unresected non-small cell lung cancer (NSCLC) at UPMC: A quality initiative by Integra Connect PrecisionQ.
First Author: Daniel P. Petro
Poster
2023 ASCO Annual Meeting
Association of immune-related adverse events and efficacy outcomes in phase II trial of consolidation nivolumab plus ipilimumab or nivolumab alone after chemoradiation in patients with unresectable stage III non–small-cell lung cancer (NSCLC).
First Author: Cynthia Wei